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Background: Olanzapine long-acting injection (LAI) for the treatment of schizophrenia was associated with a cluster
of symptoms termed post-injection delirium/sedation syndrome (PDSS) in a small percentage (~2%) of patients
during clinical trials. The objective of this analysis was to evaluate the rate and clinical characteristics of PDSS since
olanzapine LAI entered commercial use.
Methods: Cases of PDSS were identified from all reported adverse events during worldwide commercial use of
olanzapine LAI through to 1 March 2014. Data sources included two ongoing post-marketing safety studies as well
as spontaneously reported adverse events from routine clinical practice over a 5-year period (1 March 2009 to 1
March 2014).
Results: A total of 338 PDSS events were identified. Of these, 91% occurred within 1 hour of injection, and 52% of
these occurred within 15 minutes. None of the PDSS events in this analysis were fatal, and most resolved within
72 hours. The most common symptoms (occurring in >30% of cases) were sedation (61%), confusion (56%),
dysarthria (54%), somnolence (46%), dizziness (45%) and disorientation (35%). Overall, PDSS occurred with
approximately 0.07% of injections and in 0.46–1.03% of patients (reporting and incidence rates from spontaneous
reports and post-marketing safety studies, respectively).
Conclusions: The PDSS events reported during routine clinical use of olanzapine LAI are generally similar in
incidence and presentation to those reported in clinical trials. Caution should be applied when interpreting
spontaneously reported rates of adverse events, however, due to potential under-reporting. Implemented
risk-minimisation activities may contribute substantially to the identification and appropriate management of
patients with PDSS in clinical practice.
Keywords: Depot antipsychotic, Olanzapine, Olanzapine long-acting injection, Olanzapine pamoate, Post-injection
delirium/sedation syndrome, SchizophreniaBackground
Compliance with oral medication is often poor in pa-
tients suffering from illnesses such as schizophrenia,
leading to relapse and subsequent hospitalisation [1,2].
Over the past decade, a number of atypical antipsychotics
have been developed as long-acting injectable depot for-
mulations, with the intention of enhancing patient com-
pliance and improving health outcomes [1,2]. Olanzapine* Correspondence: bushe_chris@lilly.com
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Full list of author information is available at the end of the article
© 2015 Bushe et al.; licensee BioMed Central.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.long-acting injection (LAI) consists of a pamoate salt of
olanzapine that is administered by deep intramuscular in-
jection every 2–4 weeks. It has been available in 31coun-
tries for over 5 years for the treatment of schizophrenia in
adults.
Clinical trials have shown that olanzapine LAI has
comparable efficacy and safety to oral olanzapine with
the exception of adverse events related to the route of
administration [3-5]. In these trials, olanzapine LAI was
associated with a cluster of symptoms related to post-
injection delirium and/or excessive sedation in a smallThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tively referred to as post-injection syndrome or post-
injection delirium/sedation syndrome (PDSS), have been
fully defined (see list below) and appear to be consistent
with symptoms associated with an oral olanzapine over-
dose [5,6].
For a clinical diagnosis of PDSS, the following criteria
must be met [6]:
1. One or both of the conditions listed in (a) and (b):
(a)A minimum of 1 sign or symptom from at least 3
of the following symptom clusters consistent with
















2. Condition develops within 24 hours of an olanzapine
LAI.
3. Condition cannot be explained by a significant
dose increase of olanzapine LAI, initiation or
addition of oral olanzapine or other sedating
medication, or new exposure to olanzapine LAI.
4. Underlying medical conditions have been
ruled out, including concomitant substance
use or abuse.
PDSS is thought to arise as a result of accidental entry
of olanzapine into the bloodstream due to blood vessel
injury during the injection process [9], a documented
risk for intramuscular injections [10-13]. Special precau-
tions for olanzapine LAI administration are therefore
recommended [6], and two post-marketing safety studies
are underway to further evaluate the frequency, signs,
symptoms, clinical characteristics and outcomes of PDSS
in routine clinical practice.
We present an interim 5-year cohort analysis of
reported cases of PDSS from ongoing post-marketing
safety studies of olanzapine LAI, together with all cases
spontaneously reported from the time of first commer-
cial availability of olanzapine LAI through to 1 March
2014. Our objective was to investigate the occurrence
rate and clinical characteristics of PDSS in routineclinical practice and to compare these with the rates and
characteristics reported in formal clinical trials.
Methods
Overview
Cases of PDSS were identified from two post-marketing
safety studies and from spontaneous reports of adverse
events from the first introduction of olanzapine LAI to
the market, 1 March 2009, through to 1 March 2014 (a
period of 5 years), as outlined below. All reports of ad-
verse events, including all suspected cases of PDSS, were
reviewed by an adjudication committee for classification
as possible cases of the syndrome using published cri-
teria (Table 1) [6].
Post-marketing safety studies
Global observational study
Study F1D-MC-B034 (B034) is an ongoing multinational
surveillance study designed to assess the incidence of
PDSS in patients with schizophrenia treated with olanza-
pine LAI in real-world clinical practice. The study also
aims to characterise the clinical presentation and out-
comes of PDSS, and to provide insight into the possible
predictors and risk factors, if any exist. All patients
are ≥18 years of age with a diagnosis of schizophrenia
and are currently receiving olanzapine LAI in accordance
with their physician’s standard of care. Patient treatment,
dosing and adverse event management are at the discre-
tion of the investigator.
The study was approved in all countries either at the
site, regional, or national level, depending on the country
and local regulations. Patient consent followed country
regulations. The study protocol was approved by the
Ethical Review Board at each study centre Additional file 1.
The study is being conducted in full accordance with the
Declaration of Helsinki, Good Clinical Practice and applic-
able laws or regulations.
US patient care program registry
Study F1D-MC-B041 (B041) is an ongoing Patient Care
Program Registry in the US that collects data from each
olanzapine LAI administration in the country, such as
dose, date, time of administration and signs or symptoms
of PDSS. All prescribers, patients, healthcare facilities and
pharmacy service providers, who administer, or receive
olanzapine LAI in the US, are enrolled in the programme
and receive the necessary education and training to recog-
nise PDSS. Multiple methods are used to enrol and track
participants, and follow-up is performed if further infor-
mation is required to characterise a PDSS event.
Spontaneously reported cases of PDSS
Spontaneously reported cases of PDSS were captured
from Eli Lilly’s worldwide pharmacovigilance system.
Table 1 Number of cases and rate of PDSS in routine clinical practice







US Patient Care Program
Registry (B041)
Total number of injections 38,721 49,991 88,712 411,209b 499,921c
Total number of patients 2131 4001 6132 58,868d 65,000d
Number of PDSS events 19 (in 18 patients) 47 (in 45 patients) 66 (in 63 patients) 272 (in 270 patients) 338
Rate of PDSS (% of injections) 0.05 0.09 0.07 0.07e N/Af
Rate of PDSS (% of patients) 0.84 1.1 1.03 0.46g N/Af
aPost-marketing safety studies and spontaneous reports combined.
bEstimated by excluding the number of vials used in the post-marketing safety studies, and assuming that only 75% of all vials sold are used.
cIncludes estimated number of injections administered outside of the post-marketing safety studies.
dEstimated number of patients receiving an injection outside of the post-marketing safety studies.
eBased on the estimated number of injections administered outside of the post-marketing safety studies.
f Not applicable; actual rates from post-marketing safety studies and estimated rates from spontaneous reports cannot be combined.
gBased on the estimated number of patients receiving an injection outside of the post-marketing safety studies.
PDSS = post-injection delirium/sedation syndrome.
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cates information about adverse events spontaneously
reported to Eli Lilly. All reports of adverse events in pa-
tients treated with olanzapine LAI were assessed to de-
termine whether a PDSS event could have occurred and
whether the criteria for PDSS had been met using the
published criteria [6].
Data extraction and analysis
For the post-marketing safety studies, data extracted in-
cluded the total number of actively enrolled patients, the
total number of injections administered, and the total
number of PDSS events. The rate of PDSS was calcu-
lated as a percentage of the number of injections admin-
istered and as a percentage of the number of patients
receiving at least one injection.
For spontaneously reported data, the rate of PDSS
was calculated as a percentage of the estimated num-
ber of injections administered and as a percentage of
the estimated number of patients receiving at least
one injection. The number of injections was estimated
based on 75% of the total number of olanzapine LAI
vials sold minus the number of vials used in the
post-marketing safety studies. The number of patients
receiving an injection was extrapolated from olanza-
pine LAI usage patterns in the US Patient Care Program
Registry.
Additional data on PDSS extracted from the post-
marketing safety studies and spontaneous reports in-
cluded the following: number of injections received be-
fore the occurrence of PDSS; the time to initial onset of
PDSS; hospitalisation status; treatment received for
PDSS; recovery status; and symptoms. Descriptive statis-
tics were used to characterise the clinical presentation of
PDSS, including outcomes.Results
Overview
A total of 338 PDSS events were identified in 333
patients treated with olanzapine LAI between 1 March
2009 and 1 March 2014. Of the 338 events, 66 were
sourced from the two post-marketing safety studies, and
272 were spontaneous reports. The estimated number of
injections administered worldwide during this time was
499,921 and the estimated number of patients receiving
an injection worldwide was 65,000 (Table 1).
Post-marketing safety studies
A total of 88,712 injections of olanzapine LAI were
administered to 6132 patients in the two post-marketing
safety studies. Sixty-six PDSS events were reported in 63
patients, indicating that PDSS occurred with approxi-
mately 0.07% of injections, and in 1.03% of patients in
these post-marketing studies (Table 1).
Spontaneously reported cases of PDSS
Outside of clinical trials and the post-marketing safety
studies, it was estimated that 411,209 injections were
administered to 58,868 patients. A total of 272 PDSS
events were reported in 270 patients, indicating that
PDSS occurred with approximately 0.07% of injections
and in 0.46% of patients according to spontaneous
reports (Table 1).
Number of injections before occurrence of PDSS
For both the post-marketing safety studies and spontan-
eous data, PDSS events were reported most commonly
after the first 3 injections (43% of cases with a known
injection number; Table 2), but did occur after a wide
range of 1–94 injections.
Table 2 PDSS cases in routine clinical practice according
to number of injections and time to onset







Time to onset of PDSSb
≤1 hour 91 (294/323)
1–2 hours 7 (24/323)
2–3 hours 1 (4/323)




The table shows the percentage of cases of PDSS according to the number of
injections received at the time the syndrome occurred, and according to time
to onset after injection, in two post-marketing safety studies and
spontaneous reports.
aThe number of injections received before PDSS occurred was known for 193
of the 338 cases.
bThe precise time to onset of PDSS was known for 323 of the 338 cases.
PDSS = post-injection delirium/sedation syndrome.
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For both the post-marketing safety studies and spontan-
eous data, the longest reported time to onset of PDSS was
173 minutes. Since the launch of olanzapine LAI, no cases
of PDSS have been reported beyond 180 minutes after
injection. Approximately 91% of cases of PDSS presented
within the first 60 minutes (Table 2). Of the 294 cases
identified in the first 60 minutes, 52% (154/294) presented
within the first 15 minutes (Figure 1). Time to onset of
























Figure 1 Time to onset of PDSS among cases presenting in the
first 60 minutes after injection. The figure illustrates the
percentage of cases of PDSS in routine clinical practice according to
time to onset among 294 cases presenting in the first 60 minutes
after injection. PDSS = post-injection delirium/sedation syndrome.Outcomes of PDSS events
For both the post-marketing safety studies and spontan-
eous data, there were no fatal outcomes. Injections were
administered in healthcare facilities outside a hospital
setting in 93% of cases (316/338 cases), and in hospital
in 7% of cases (22/338). Of the 316 cases receiving an in-
jection outside hospital, 65% (206/316) required subse-
quent hospitalisation as a result of PDSS events. Patients
who developed PDSS following an in-hospital injection
(22 cases) remained in hospital; it is not known whether
these events in themselves would have merited hospital-
isation or an extension of hospitalisation. Twelve per-
cent (39/338) of the cases of PDSS were treated in an
Emergency Department with no report of subsequent
hospitalisation. Eighteen percent of cases (60/338) did
not require hospitalisation. The duration of hospitalisa-
tion was known for 44% (149/338) of the hospitalised
cases; in 52% (77/149) of these it was ≤24 hours.
Management of PDSS was documented for 72% (243/
338) of cases; a large number of these cases required
either no treatment or only continued monitoring with
or without intravenous fluids (Table 3). Medications
were administered as a treatment for PDSS in 31% (75/
243) of cases, and included beta-agonists, benzodiaze-
pines, diuretics and anticholinergics. A sedative drug
(benzodiazepine or antipsychotic) was given in 19% (45/
243) of cases. A small percentage of cases (5%; 13/243)
required intubation/ventilation. This was administered
prophylactically in approximately half of the cases (6
cases: 5 due to the patient being unconscious/comatose
and 1 due to the patient requiring sedation for severe
agitation) and for respiratory distress in the remaining
cases (7 cases: 6 as a result of airway blockage or aspir-
ation, and 1 as a result of poor oxygenation due to
severe agitation). Data on continuation of olanzapineTable 3 Treatments administered during PDSS events in
routine clinical practice
Treatment Percentage of casesa
No treatment 19 (47/243)
Medication 31 (75/243)
Potentially sedative drug 19 (45/243)
Intravenous fluids 25 (60/243)
Monitoring 21 (51/243)
Oxygen 5 (13/243)
Physical restraint 4 (9/243)
Admission to intensive care unit 18 (44/243)
Ventilation/intubation 5 (13/243)
The table shows the treatment requirements for PDSS in the 243 cases where
treatment data were available from two post-marketing safety studies and
spontaneous reports.
aSome cases involved more than one type of treatment, and are therefore
included more than once in the table.
PDSS = post-injection delirium/sedation syndrome.
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was continued in 55% of these cases (116/210).
Recovery status was reported for 94% (318/338) of
PDSS cases; 98% (311/318) of patients with recovery
status data had a full recovery which took ≤ 72 hours
in 88% (273/311) of these cases. The time to recovery
was unknown in 10% (30/311) of cases. Seven of the
318 patients with recovery status data were reported
as not being recovered on the day of the report, and
recovery outcome was unknown for the remaining
20 cases.
Signs and symptoms of PDSS
In both the post-marketing safety studies and spontan-
eous reports, the symptoms of PDSS were consistent
with those observed in clinical trials and those associ-
ated with an oral olanzapine overdose [4,5]. The most
frequently observed symptoms were assessed as being
related to delirium and excessive sedation (Figure 2).
Delirium-related symptoms included ataxia, cognitive
disorder, confusional state, delirium, disorientation, dis-
turbance in attention, dysarthria and speech disorder.
Delirium-related symptoms were reported in 86% (290/
338) of cases, sedation-related symptoms in 89%
(299/338) of cases and both types of symptoms in 74%
(251/338) of cases. All cases of PDSS involved either
sedation- or delirium-related symptoms.
Other clinical events reported in ≥5% of cases
(expressed as a percentage of the 338 PDSS events) were
dizziness (45%), agitation (30%), asthenia (25%), anxiety
(18%), gait disturbance (17%), fatigue (17%), tachycardia
(13%), restlessness (12%), hypertension (10%), akathisia

















Figure 2 Most frequently reported symptoms of PDSS in routine clini
symptoms, expressed as a percentage of the total number of PDSS events (n
syndrome.symptoms (8%), increased heart rate (7%), malaise (7%),
and nausea (6%).
Discussion
The results of the current analysis show that the
occurrence rate and clinical characteristics of PDSS in
real-world clinical practice are consistent with those
observed in formal clinical trials of olanzapine LAI,
as summarised in Table 4. Indeed, the rate of PDSS
per-injection appears to have remained consistent
throughout the clinical trials and post-marketing use,
at 0.05–0.09% of injections. The per-patient rate in
clinical practice (0.46–1.03% of patients) and in clinical
trials (1.4–2% of patients, based on reporting rates
from spontaneous reports and incidence rates from
post-marketing safety studies, respectively) were also
generally consistent, taking into consideration the
shorter length of commercial use at present relative to
the longer average exposures in clinical trials, in which
patients were treated for up to 6 years [5-8]. As a PDSS
event can occur with any injection, the per-patient rate
would be expected to increase as individual patients
receive more injections.
In our analysis, the majority (91%) of PDSS cases
presented within 60 minutes of injection and, of these,
around half (52%) presented within the first 15 minutes.
This is consistent with the timings observed in clinical
trials, where 80% of cases occurred within 60 minutes of
an injection, and the mean and median times to the on-
set of symptoms were 49 and 25 minutes, respectively
[6]. In addition, the majority of cases of PDSS in our
analysis (73%) were reported following the first 9 injec-






cal practice. The figure illustrates the most frequently reported
= 338), in routine clinical practice. PDSS = post-injection delirium/sedation
Table 4 Comparison of characteristics of PDSS in routine





Rate of PDSS (% of injections) 0.07% 0.07–0.09%
Rate of PDSS (% of patients) 0.46–1.03% 1.4–2.0%
Cases starting within 60 minutes
of injection
91% 80%




Cases showing recovery within
72 hours
88% 100%
Cases involving delirium-related AEs 86% 97%
Cases involving sedation-related AEs 89% 87%
Cases involving delirium &
sedation-related AEs
74% 83%
AE = adverse event; PDSS = post-injection delirium/sedation syndrome.
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number at which a PDSS event occurred was 21 [6].
The symptoms of PDSS in clinical practice were similar
to those observed in previous clinical trials [6], with a
clinical presentation consistent with symptoms of olanza-
pine overdose. As in the clinical trials [6], all cases in
the present analysis included either sedation- or delirium-
related symptoms, with most cases including both
(Table 4). In the cases of PDSS reported by Detke et al.
[6], no clinically significant decreases in blood pressure,
heart rate or respiration were reported. In the present ana-
lyses, however, a small number of patients required intub-
ation due to respiratory distress. In the post-marketing
safety studies, a range of changes in blood pressure was
noted, with some patients experiencing hypertension and
others experiencing hypotension. However, changes in
blood pressure are not considered a defining feature of
PDSS [6]. It should also be noted that in 40% of cases in
the clinical trials, the initial symptoms of PDSS were not
related to sedation or delirium but presented as general
malaise, anxiety, agitation or irritability. Thus, as the early
symptoms of PDSS may not be immediately obvious and
cannot be measured through changes in vital signs, con-
tinued patient observation offers the best approach for
early detection of PDSS.
The outcomes for patients with PDSS in routine clin-
ical practice were also similar to those in clinical trials:
none of the PDSS events were fatal, and most resolved
within 72 hours. Similarly, the signs and symptoms of
PDSS in routine clinical practice were consistent with
those observed in clinical trials, and with those reported
in cases of olanzapine overdose [5,6]. It should be noted
that two deaths were reported in patients taking olanza-
pine LAI, in whom post-mortem blood samples revealed
elevated olanzapine concentrations [14]. However, neithercase was adjudicated as being a PDSS event, as there was
no evidence to support this possibility. Because post-
mortem olanzapine concentrations in the blood tend to
rise as a result of post-mortem redistribution from other
sites in the body [15,16], the post-mortem data could not
be considered to reflect the likely concentrations before
death [17]. Nevertheless, it is important to be aware that
the potential for death, although small, always exists with
olanzapine overdose, and thus patients with PDSS should
be managed with appropriate care.
As a result of the emergence of PDSS, prescribing
information for olanzapine LAI contains appropriate
warnings and country-specific monitoring requirements.
In addition, all prescribers of olanzapine LAI are required
to undertake country-specific education and training to
enable them to identify and manage the signs and symp-
toms of PDSS. Olanzapine LAI must be administered in
a healthcare facility with ready access to emergency re-
sponse services, and all patients are required to undergo
observation for a period of time by an appropriately
qualified healthcare professional after receiving an injec-
tion [7,8]. If PDSS is suspected, close medical supervision
and monitoring should continue until examination indi-
cates that the signs and symptoms have resolved. Since no
clear risk factors and no concomitant medications have
been identified as predictors of PDSS, observation must
be undertaken in all patients after every injection [6-9].
As PDSS most likely occurs as a result of a portion of
the olanzapine dose entering the bloodstream [9], use of
the correct injection technique is important [6]. Conse-
quently, prescribers of olanzapine LAI are also required
to receive training on the correct injection technique.
Accidental intravascular injection is a known risk for all
drugs that are administered by intramuscular injection,
and has been reported with penicillins, promethazine,
benzodiazepines and barbiturates [10-13].
Limitations of the current analysis include the likeli-
hood of under-reporting for spontaneous data, which
rely on patients and/or healthcare providers contacting
Eli Lilly or regulatory authorities. In addition, the identi-
fication of PDSS from spontaneous reports relies on
sufficient details being provided by the person reporting
the case [18]. Thus, while some cases reported as
possible PDSS may not have been adjudicated as being a
confirmed PDSS case because the reported symptoms
did not meet the established criteria, others could not be
confirmed because of insufficient information. Also, be-
cause exact denominators (total number of patients and
total number of injections) are not known, rate calcula-
tions rely on the use of estimates. Thus, the results from
spontaneous data should be viewed with caution. By con-
trast, data from the formal post-marketing safety studies
are more accurate and of higher quality as they are
collected from a known number of patients receiving a
Bushe et al. BMC Psychiatry  (2015) 15:65 Page 7 of 8known number of injections using a standard report-
ing format. Nevertheless, despite the limitations of
spontaneous reporting data, the per-injection rates of
PDSS are almost identical across the various sources,
supporting the probable validity of the spontaneous
reporting findings.
Another limitation is that longer exposures oc-
curred in the clinical trials than are yet available during
post-marketing use; however, substantially greater num-
bers of patients have now been exposed in post-
marketing use (over 60,000) than in the clinical trials
(2,054 [6]).
Despite these limitations, the rate, clinical presentation
and outcomes of PDSS were generally consistent with
those seen in clinical trials. This suggests that there is
good awareness of PDSS among healthcare providers and
that the PDSS educational programme for healthcare
providers is encouraging active identification and manage-
ment of the syndrome.Conclusions
Olanzapine LAI has been in routine clinical use for over
5 years, and a large body of safety data is now available
from a number of different countries and a variety of
clinical settings. The current analysis has shown that the
rate (both per-injection and per-patient), outcome and
presentation of PDSS events being reported during rou-
tine clinical use of olanzapine LAI are similar to those
reported in clinical trials. To date there have been no fa-
talities associated with confirmed PDSS events, and most
events continue to appear temporary in nature, typic-
ally resolving in less than 72 hours. Adherence to the
labelled conditions and precautions of use as well as
risk-minimisation measures will continue to allow
appropriate identification, diagnosis and management of
PDSS cases.Endnote
aOther signs and symptoms not listed under 1a may
occur with olanzapine overdose but are not considered
criteria for PDSS. See olanzapine prescribing information.Additional file
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